期刊文献+

大黄蟅虫丸抗四氯化碳致大鼠肝纤维化的实验研究 被引量:6

Protective Effects of Dahuangzhechongwan against Rat Hepatic Fibrosis Induced by Carbon Tetrachloride
下载PDF
导出
摘要 目的探讨大黄蟅虫丸抗肝纤维化的作用机理。方法建立四氯化碳(CCl4)复合因素肝纤维化大鼠模型,观察大黄蟅虫丸对模型动物转化生长因子β1(TGFβ1)、基质金属蛋白酶组织抑制因子1(TIMP-1)的影响。结果大黄蟅虫丸能显著抑制大鼠血清中的TGFβ1、TIMP-1、透明质酸酶(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、IV型胶原(CIV)、谷丙转氨酶(ALT)、谷草转氨酶(AST)的表达。结论大黄蟅虫丸对肝纤维化形成中两个重要因子TGFβ1和TIMP-1表达的抑制作用,可能是其抗肝纤维化的作用机理之一。 ObjectiveTo explore the protective mechanism of Dahuangzhechongwan on hepatic fibrosis. MethodsRat fibrosis model was established by CCl4 compound factors.Transforming growth factor β1(TGFβ1),tissue inhibitor of metalloproteinase-1(TIMP-1) were detected in the serum among different groups. ResultsDahuangzhechongwan could reduce the serum levels of TGFβ1,TIMP-1,Hyaluronic Acid(HA),Laminin(LN),Procolagen Type Ⅲ(PCⅢ),Collagen TypeⅣ(CⅣ),glutamic-pyruvic transaminase(ALT) and glutamic-oxalacetic transaminase(AST),respectively. ConclusionDahuangzhechongwan can inhibit the expression of TGFβ1 and TIMP-1,the two main factors were related to the occurrence of hepatic fibrosis.This may be one of the mechanisms which Dahuangzhechongwan restrains the progression of liver fibrosis.
出处 《时珍国医国药》 CAS CSCD 北大核心 2012年第4期801-802,共2页 Lishizhen Medicine and Materia Medica Research
基金 国家自然科学基金(No.30271627) 广东省自然科学基金(No.020337)
关键词 大黄蟅虫丸 肝纤维化 转化生长因子Β1 基质金属蛋白酶组织抑制因子1 Dahuangzhechongwan Hepatic fibrosis TGFβ1 TIMP-1
  • 相关文献

参考文献9

  • 1陈孝银,李恩庆,沈强,章群,孙立,徐云生.大黄虫庶虫丸抑制乙型肝炎后肝纤维化的临床研究[J].中国病理生理杂志,2005,21(5):1018-1019. 被引量:15
  • 2徐乾,朱平,张斌,杜建霞,李芳,蒋淑莲.大黄虫丸抗肝纤维化临床疗效观察[J].时珍国医国药,2006,17(5):808-809. 被引量:13
  • 3程明亮.肝纤维化的基础研究与临床[M].北京:人民卫生出版社,1994.40-42.
  • 4吕志平,贺松其,张绪富,赵进军.保肝宁抗肝纤维化的治疗作用探析[J].上海中医药杂志,2005,39(5):6-8. 被引量:20
  • 5Wells RG.Cellular sources of extracellular matrix in hepatic fibrosis[J].Clin Liver Dis,2008,12(4):759.
  • 6Consolo M,Amoroso A,Spandidos DA,et al.Matrix metalloproteinasesand their inhibitors as markers of inflammation and fibrosis in chronicliver disease[J].Int J Mol Med,2009,24(2):143.
  • 7Mannello F,Jung K.Blood sampling affects circulating TIMP-1 con-centration,a useful biomarker in estimating liver fibrosis stages[J].Hepatology,2008,48(2):688.
  • 8De Minicis S,Candelaresi C,Marzioni M,et al.Role of endogenous opi-oids in modulating HSC activity in vitro and liver fibrosis in vivo[J].Gut,2008,57(3):352.
  • 9Rallón NI,Barreiro P,Soriano V,et al.Elevated TGF-β1 levels mightprotect HCV/HIV-coinfected patients from liver fibrosis[J].Eur JClin Invest,2011,41(1):70.

二级参考文献26

共引文献45

同被引文献80

引证文献6

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部